Educational Webinars-Hematology
This multimedia content is made available for HCPs specializing in oncology for learning and information purposes only to address the need of the medical community to better understand investigational interventions and the physiology of disease
View Educational Webinars from GSK oncology
Multiple Myeloma Conversations Webinar on BCMA-Targeted Therapies in Relapsed Refractory Multiple Myeloma
Learn about ways to maximize efficacy, moderate adverse events, and improve the patient experience when using novel BCMA-targeted therapies in RRMM. This webinar/symposium was originally delivered on November 30, 2021, when BLENREP monotherapy was approved in the US for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US as of February 6, 2023. BLENREP monotherapy is still indicated in the EU for the treatment of RRMM.
European Hematology Association (EHA) 2023 Symposium on Addressing the Challenges of Anaemia and Thrombocytopenia in Myelofibrosis
Learn more about the significant burden of anemia and thrombocytopenia on patients and the current and emerging treatment options in MF in addition to case presentations followed by an expert panel discussion.
Multiple Myeloma Conversations Webinar on the Latest anti-BCMA Therapy Data from ASCO & EHA 2023
Learn more about recent BCMA-targeted monotherapy datasets presented at ASCO & EHA 2023, including DREAMM-3
European Hematology Association (EHA) 2023 Symposium on Novel BCMA-based Combination Therapies in Early Relapsed Refractory Multiple Myeloma
Learn more about novel BCMA-based combination regimens in early RRMM, and real-world practical approaches to improving the benefit-risk profile with BCMA-targeted agents in earlier lines of therapy
Multiple Myeloma Conversations Webinar on Real World Evidence for the use of BCMA-Targeted Therapies in Relapsed Refractory Multiple Myeloma
Learn more about emerging real-world evidence data for BCMA-targeted agents and practical considerations for selection of BCMA-targeted therapies in RRMM
Controversies in Multiple Myeloma (COMy) 2023 Symposium on Novel BCMA-based Combination Therapies in Early Relapsed Refractory Multiple Myeloma
Learn more about the changing treatment landscape associated with multiple myeloma, and novel BCMA-based combination regimens in early RRMM
Multiple Myeloma Conversations Webinar on Novel MOAs in Relapsed Refractory Multiple Myeloma
Learn about the clinical impact of re-treating with the same therapy class in RRMM, as well as, BCMA-targeting agents with novel MOAs as an alternative to re-treatment in RRMM. This webinar/symposium was originally delivered on September 14, 2022, when BLENREP monotherapy was approved in the US for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US as of February 6, 2023. BLENREP monotherapy is still indicated in the EU for the treatment of RRMM.
Controversies in Multiple Myeloma (COMy) 2022 Symposia on Unlocking the Potential of Novel BCMA combinations
Learn about the changing multiple myeloma therapeutic landscape, and the potential of novel BCMA combinations in multiple myeloma. This webinar/symposium was originally delivered on May 13, 2022, when BLENREP monotherapy was approved in the US for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US as of February 6, 2023. BLENREP monotherapy is still indicated in the EU for the treatment of RRMM.
European Hematology Association 2022 on Potential Novel Combination Treatment in Multiple Myeloma
Learn about the dynamic landscape in multiple myeloma, integration of BCMA-targeted agents in early relapsed refractory multiple myeloma, and optimizing the benefit-risk profile and feasibility of sequencing of BCMA-targeted agents. This webinar/symposium was originally delivered on June 9, 2022, when BLENREP monotherapy was approved in the US for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US as of February 6, 2023. BLENREP monotherapy is still indicated in the EU for the treatment of RRMM.
Multiple Myeloma Conversations Webinar on Understanding Real-World Evidence in Triple-Class Relapsed Refractory Multiple Myeloma
Learn about the changing multiple myeloma therapeutic landscape, the importance of real-world evidence, and emerging real-world datasets for agents recently approved for the treatment of triple-class exposed/refractory multiple myeloma. This webinar/symposium was originally delivered on April 20, 2022 when BLENREP monotherapy was approved in the US for the treatment of RRMM. Please be aware that BLENREP monotherapy is no longer approved for any indication in the US as of February 6, 2023. BLENREP monotherapy is still indicated in the EU for the treatment of RRMM.
SE-GBL-ON-WCNT-200001 | June 2023